Cyprotex
Macclesfield
About Cyprotex
Cyprotex specialises in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling). Cyprotex was founded in 1999, and in 2002 it was listed on the London Stock Exchange’s AIM Market (symbol CRX, information for investors). Our headquarters are in Macclesfield, UK, near Manchester.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Total funding: $2.7M
- Funding stage: M&A
- Last round: Series Unknown (Aug 2010)
- Ticker: lse:CRX
- Website: cyprotex.com
- Phone: +44 1625 505100
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cyprotex-920469 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.